Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer.
Int J Clin Oncol
; 22(3): 494-504, 2017 Jun.
Article
in En
| MEDLINE
| ID: mdl-28078540
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Colonic Neoplasms
/
Capecitabine
/
Antimetabolites, Antineoplastic
Type of study:
Clinical_trials
/
Etiology_studies
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Year:
2017
Type:
Article